ContraFect Corp.
(NASDAQ : CFRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.83%301.871.4%$585.84m
AMGNAmgen, Inc.
0.03%233.481.3%$518.07m
GILDGilead Sciences, Inc.
1.70%67.051.0%$369.78m
REGNRegeneron Pharmaceuticals, Inc.
1.03%372.132.6%$303.58m
VRTXVertex Pharmaceuticals, Inc.
-0.79%221.321.9%$266.02m
ILMNIllumina, Inc.
1.86%325.773.5%$237.43m
ARWRArrowhead Pharmaceuticals, Inc.
1.22%66.3312.0%$189.50m
EXASEXACT Sciences Corp.
2.17%85.4224.0%$182.30m
CLVSClovis Oncology, Inc.
11.74%9.9014.7%$181.15m
ALXNAlexion Pharmaceuticals, Inc.
4.65%112.412.0%$178.03m
SRPTSarepta Therapeutics, Inc.
-0.45%109.4714.6%$148.16m
AAgilent Technologies, Inc.
0.68%82.081.6%$141.44m
BMRNBioMarin Pharmaceutical, Inc.
0.92%80.824.3%$131.30m
NBIXNeurocrine Biosciences, Inc.
0.88%117.515.0%$128.69m
SGENSeattle Genetics, Inc.
0.23%117.436.1%$128.18m

Company Profile

ContraFect Corp. is a clinical stage biotechnology company , which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.